Overview

Erythropoietin in Hemolytic Uremic Syndrome

Status:
Completed

Trial end date:
2020-12-30

Target enrollment:

Participant gender:

Summary

This study will evaluate the impact of early administration of erythropoietin in the number of red blood cell transfusions in children with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome (STEC-HUS).

Phase:

Phase 4

Details

Lead Sponsor:

Hospital General de Niños Pedro de Elizalde

Treatments:

Epoetin Alfa